Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 20/20 | 0.54 |
| ▸ | WNT3A | P56704 | 11/20 | 0.54 |
| ▸ | TNKS | O95271 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18701496 | 0.85 | TNKS2 (0.39) | TNKS2WNT3ATNKS | |
| SCHEMBL18701518 | 0.80 | MAPT (0.43) | TNKS2WNT3ATNKS | |
| SCHEMBL7776894 | 0.79 | TNKS2 (0.61) | TNKS2WNT3ATNKS | |
| SCHEMBL17986449 | 0.78 | TNKS2 (0.57) | TNKS2WNT3ATNKS | |
| SCHEMBL12030971 | 0.77 | MAPT (0.53) | TNKS2WNT3ATNKS | |
| SCHEMBL18701482 | 0.77 | HPGD (0.50) | TNKS2WNT3ATNKS | |
| SCHEMBL14638069 | 0.76 | TNKS2 (0.54) | TNKS2WNT3ATNKS | |
| SCHEMBL28502054 | 0.76 | TNKS2 (0.54) | TNKS2WNT3ATNKS | |
| SCHEMBL20363018 | 0.76 | TNKS2 (0.54) | TNKS2WNT3ATNKS | |
| SCHEMBL17011678 | 0.76 | TNKS2 (0.54) | TNKS2WNT3ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | WNT1, TNKS1BP1, TNKS | TNKS2 4/4885WNT3A 17/4885TNKS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.